SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immucell (ICCC) - Potential Treatment for Cryptosporidium
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ed who wrote (11)4/24/1997 9:34:00 AM
From: Jonathan Rothschild   of 46
 
Check out their earnings report this morning. Q1 EPA 6 cents/share. R & D expenses were down for the quarter. If they did nothing, they would still be profitable. This year they will start a revenue stream from lactoferrin and their crypto water test.The study with the navy excites me. A comparable study would cost at least 5 MM and the navy kicks in the personnel with objective credibility. I've heard that the Navy's Cooperative Research and Development Agreements are extremely hard-to-get for a biotech company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News